Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR). Despite initial responses. patients eventually progress by unknown mechanisms of "acquired" resistance. We show that in two of fiv... https://safeersappliancers.shop/product-category/microwave/